An observational study in Depression and Autoimmune Diseases, sponsored by HaEmek Medical Center, Israel. Recruiting at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-24.
Sponsored by HaEmek Medical Center, Israel · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Depression with a site in Israel — 8 open to participants now, 10 under way, none of them phase 3. Depression · Israel.
Among the 72 studies in Depression with a site in Israel, this one is the 8th largest by planned enrollment of the 16 observational ones that give a count, is one of 4 that started in 2022, is one of 16 observational ones, and was the 58th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →8 of the 72 studies in Depression with a site in Israel are open now. Recruiting first, the newest first:
GrayMatters Health Ltd. · Sites in Israel, United States
Ages 22–75
Hebrew University of Jerusalem · Sites in Israel
Ages 65+ · Healthy volunteers
Assaf-Harofeh Medical Center · Sites in Israel
Ages 50–85
Bar-Ilan University, Israel · Sites in Israel, United States
Ages 18+
University of Haifa · Sites in Israel
Ages 12–18
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 4 · Phase 4 6
First in 2003; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 175 across 1,261 observational studies indexed under Depression.
Median enrollment 60 across the 56 interventional studies, 200 across the 16 observational. Of the 31 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 72 have an industry lead sponsor. The 10 most frequent:
HaEmek Medical Center, Israel is the lead sponsor of 237 studies on the registry; 11 are open to participants now.
HaEmek Medical Center, Israel has 2 studies filed under Depression — fewer than ten, so there is no comparison to draw.
2 of the studies in Depression with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06982820GrayMatters Health Ltd.Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia | 2027-05-30 |
| NCT07913425University of HaifaExamining the Effectiveness of a Brief Therapeutic Intervention for Reducing Self-Harm Among Adolescents | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 72 studies in Depression with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
It has long been claimed that depression, and other psychiatric illness, might be a manifestation of immune dysregulation involving the Central nervous system. Depression is associated with a significantly increased risk of autoimmune disease compared to those without a history of depression. The increased risk of autoimmune diseases is during the first year following the onset of depression .Conversely, up to 50% of patients with autoimmune diseases show an impairment of health-related quality of life and exhibit depressive symptoms.
The aggregation of depression and some specific autoimmune diseases may demonstrate shared inherited pathogenesis.
The first phase of the study will include patients with the diagnosis of depression. The control group will consist of a healthy population, according to medical records and will be recruited through a recruitment ad and volunteers. In the second phase of the study first and second-degree relatives (parents, siblings, children, grandparents, aunts, uncles and cousins) who are diagnosed with autoimmune disease/s will be recruited. Auto-immune diseases will include - Rheumatoid Arthritis (RA), juvenile idiopathic arthritis JIA), Seronegative spondyloarthropathies (SPA) including inflammatory bowel disease (IBD), psoriatic arthritis (PsA), and ankylosing spondylitis. Other autoimmune diseases: Systemic Lupus Erythematosus, Sjogren' syndrome (SS), systemic sclerosis (SSc), inflammatory myopathies (IIM), any Overlap of the above including mixed connective tissue disease (MCTD), systemic vasculitis (see Chapel Hill classification criteria). All autoimmune diseases will be confirmed by an expert rheumatologist or an internist. Celiac disease, Diabetes Mellitus type I, autoimmune thyroiditis, autoimmune hepatitis will be confirmed by a gastroenterologist, endocrinologist or an internist.
The first phase of the study will include patients with the diagnosis of depression. The control group will consist of a healthy population, according to medical records and will be recruited through a recruitment ad and volunteers. In the second phase of the study first and second-degree relatives (parents, siblings, children, grandparents, aunts, uncles and cousins) who are diagnosed with autoimmune disease/s will be recruited.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Depending on the primary results in the proteomic and the metabolic profiling, this pilot study will search for genetic associations, using an exome sequencing approach to individuals. The findings will be compared to individuals without depression, and to relatives of depressed patients who suffer from autoimmune diseases.
1. Find genetic association or genetic basis to depression associated with autoimmune diseases
1. Find genetic association or genetic basis to depression associated with autoimmune diseases
Time frame: 1 day
Started Feb 2022 (actual). Primary completion is estimated for Feb 2026, 48 months after the start.
Of 463 non-industry observational studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 48 months is above that.
Counting every sponsor, half of 496 studies reached it within 32 months; a quarter within 13 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
HaEmek Medical Center, Israel →